Medtech company Imricor (ASX: IMR) has been awarded a contract from the US National Institutes of Health (NIH) to advance their leading MRI technology into a prototype device that can biopsy the inner walls of the heart. The awarded contract will see Imricor receive USD $399,539 over the next 12 months for the project where
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.